Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis

International Journal of Molecular Medicine

Volumn 34, Issue 3, 2014, Pages 651-660

  Sommer, Jan ^a   Engelowski, Erika ^a   Baran, Paul ^a   Garbers, Christoph ^b   Floss, Doreen M ^a   Scheller, Jürgen ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Animal model; Cytokine; Dextran sodium sulfate; Inflammation; Ulcerative colitis

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CRE RECOMBINASE; DEXTRAN; DEXTRAN SULFATE; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INTEGRASE; INTERLEUKIN-6, MOUSE; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE PREDISPOSITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE REGENERATION; WEIGHT REDUCTION; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; COLON; DEFICIENCY; DRUG EFFECTS; MALE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; COLITIS; COLON; DEXTRAN SULFATE; DEXTRANS; DISEASE SUSCEPTIBILITY; FLUORESCEIN-5-ISOTHIOCYANATE; INTEGRASES; INTERLEUKIN-6; MALE; MICE, INBRED C57BL; ORGAN SPECIFICITY; RECEPTORS, INTERLEUKIN-6; WEIGHT LOSS;

EID: 84905048976     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1825     Document Type: Article

References (33)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
2. Shapira Y, Agmon-Levin N and Shoenfeld Y: Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34: J168-J177, 2010.
3. Danese S, Sans M and Fiocchi C: Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 3: 394-400, 2004. (Pubitemid 38993362)
4. Mudter J and Neurath MF: Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13: 1016-1023, 2007. (Pubitemid 47309974)
5. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP and Raedler A: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174-181, 1993. (Pubitemid 23308385)
6. Mudter J and Neurath MF: Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 56: 293-303, 2007.
7. Yamamoto M, Yoshizaki K, Kishimoto T and Ito H: IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878-4882, 2000. (Pubitemid 30238092)
8. Ito H: Novel therapy for Crohn's disease targeting IL-6 signalling. Expert Opin Ther Targets 8: 287-294, 2004.
9. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S and Neurath MF: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6: 583-588, 2000. (Pubitemid 30305911)
10. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, Handa K, Tsuruta O, Funabashi H, Scheller J, Toyonaga A and Sata M: STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 55: 1263-1269, 2006. (Pubitemid 44277357)
11. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113, 2009.
12. Naito Y, Takagi T, Uchiyama K, Kuroda M, Kokura S, Ichikawa H, Yanagisawa R, Inoue K, Takano H, Satoh M, Yoshida N, Okanoue T and Yoshikawa T: Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 14: 191-196, 2004.
13. Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grötzinger J, Rose-John S and Kallen KJ: Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an α-receptor for CTNF. J Biol Chem 278: 9528-9535, 2003. (Pubitemid 36800446)
14. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Holscher C, Rose-John S, Grötzinger J, Lorenzen I and Scheller J: An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem 288: 4346-4354, 2013.
15. Crabé S, Guay-Giroux A, Tormo AJ, Duluc D, Lissilaa R, Guilhot F, Mavoungou-Bigouagou U, Lefouili F, Cognet I, Ferlin W, Elson G, Jeannin P and Gauchat JF: The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J Immunol 183: 7692-7702, 2009.
16. McFarland-Mancini MM, Funk HM, Paluch AM, Zhou M, Giridhar PV, Mercer CA, Kozma SC and Drew AF: Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol 184: 7219-7228, 2010.
17. Wirtz S, Neufert C, Weigmann B and Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc 2: 541-546, 2007. (Pubitemid 47040018)
18. Perse M and Cerar A: Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol 2012: 718617, 2012.
19. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S and Eigler A: Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-ã and TNF-á production. Am J Physiol Regul Integr Comp Physiol 281: R1264-R1273, 2001.
20. Clausen BE, Burkhardt C, Reith W, Renkawitz R and Forster I: Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8: 265-277, 1999. (Pubitemid 29523965)
21. Schwenk F, Baron U and Rajewsky K: A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 23: 5080-5081, 1995. (Pubitemid 26012492)
22. Moolenbeek C and Ruitenberg EJ: The 'Swiss roll': a simple technique for histological studies of the rodent intestine. Lab Anim 15: 57-59, 1981. (Pubitemid 11185576)
23. Montbarbon M, Pichavant M, Langlois A, Erdual E, Maggiotto F, Neut C, Mallevaey T, Dharancy S, Dubuquoy L, Trottein F, Cortot A, Desreumaux P, Gosset P and Bertin B: Colonic inflammation in mice is improved by cigarette smoke through iNKT cells recruitment. PLoS One 8: e62208, 2013.
24. Rani R, Smulian AG, Greaves DR, Hogan SP and Herbert DR: TGF-â limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Eur J Immunol 41: 2000-2009, 2011.
25. Raab Y, Hallgren R and Gerdin B: Enhanced intestinal synthesis of interleukin-6 is related to the disease severity and activity in ulcerative colitis. Digestion 55: 44-49, 1994. (Pubitemid 24014640)
26. Schürmann G, Betzler M, Post S, Herfarth C and Meuer S: Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations. Digestion 51: 51-59, 1992.
27. Wang S, Zhou T, Zhai JP, Wang LH and Chen J: Effects of Modified Sanhuang Decoction enema on serum tumor necrosis factor-α and colonic mucosa interleukin-1β, interleukin-6 levels in ulcerative colitis rats. Chin J Integr Med: Oct 14, 2014 (Epub ahead of print).
28. Lee MJ, Lee JK, Choi JW, Lee CS, Sim JH, Cho CH, Lee KH, Cho IH, Chung MH, Kim HR and Ye SK: Interleukin-6 induces S100A9 expression in colonic epithelial cells through STAT3 activation in experimental ulcerative colitis. PLoS One 7: e38801, 2012.
29. Nesbitt JE, Fuentes NL and Fuller GM: Ciliary neurotrophic factor regulates fibrinogen gene expression in hepatocytes by binding to the interleukin-6 receptor. Biochem Biophys Res Commun 190: 544-550, 1993. (Pubitemid 23209645)
30. Ohta K, Hara H, Hayashi K, Itoh N, Ohi T and Ohta M: Tissue expression of rat ciliary neurotrophic factor (CNTF) mRNA and production of the recombinant CNTF. Biochem Mol Biol Int 35: 283-290, 1995. (Pubitemid 26177796)
31. Shapiro L, Panayotatos N, Meydani SN, Wu D and Dinarello CA: Ciliary neurotrophic factor combined with soluble receptor inhibits synthesis of proinflammatory cytokines and prostaglandin-E2 in vitro. Exp Cell Res 215: 51-56, 1994. (Pubitemid 24339172)
32. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, Rieckmann P, Lassmann H, Toyka KV, Sendtner M and Gold R: CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 8: 620-624, 2002. (Pubitemid 34633441)
33. Kuhlmann T, Remington L, Cognet I, Bourbonniere L, Zehntner S, Guilhot F, Herman A, Guay-Giroux A, Antel JP, Owens T and Gauchat JF: Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis. Am J Pathol 169: 584-598, 2006. (Pubitemid 44156316)